计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab170530-100μg |
100μg |
现货 ![]() |
| |
| Ab170530-1mg |
1mg |
现货 ![]() |
| |
| Ab170530-5mg |
5mg |
现货 ![]() |
| |
| Ab170530-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Etrolizumab (anti-α4β7), 整合素 α4β7抑制剂;整合素α7亚基抗体;整合素αEβ7抗体 |
|---|---|
| 别名 | Etrolizumab(抗α4β7) |
| 英文别名 | Antigen CD49D antibody | CD49d antibody | IA4 antibody | Integrin alpha 4 subunit antibody | Integrin alpha IV antibody | Integrin beta 7 antibody | Integrin beta 7 subunit antibody | ITGA4 antibody | ITGB7 antibody | LPAM1 antibody | 269C wild type | CD4 |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | Integrin α4β7 |
| 应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| 种属反应性 | 人(Human) |
| 偶联 | Unconjugated |
| 作用类型 | 拮抗剂 |
| 作用机制 | 整合素 α4β7抑制剂;整合素α7亚基抗体;整合素αEβ7抗体 |
| 抗体类型 | Primary antibody |
|---|---|
| 克隆类型 | 重组抗体 |
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 27.0 kDa (Light Chain) & 51.3 kDa (Heavy Chain), under reducing conditions; 177.9 kDa, under non-reducing conditions. |
| 纯化方法 | Protein A purified |
| 纯度 | >95% |
| 来源 | CHO supernatant |
| 物理外观 | Liquid |
| 储存缓冲液 | Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0 |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1044758-60-2 |
| 分子类型 | 抗体 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 24-10-09 | Ab170530 | |
| 分析证书 | 24-10-09 | Ab170530 | |
| 分析证书 | 23-10-13 | Ab170530 | |
| 分析证书 | 23-10-13 | Ab170530 |
| 1. Schön MP, Arya A, Murphy EA, Adams CM, Strauch UG, Agace WW, Marsal J, Donohue JP, Her H, Beier DR et al.. (1999) Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice.. J Immunol, 162 (11): (6641-9). [PMID:10352281] |
| 2. Hu MC, Crowe DT, Weissman IL, Holzmann B. (1992) Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer's patch-specific lymphocyte homing.. Proc Natl Acad Sci USA, 89 (17): (8254-8). [PMID:1518854] |
| 3. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Paré P, McDonald JW, Dubé R, Cohen A, Steinhart AH, Landau S et al.. (2005) Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.. N Engl J Med, 352 (24): (2499-507). [PMID:15958805] |
| 4. Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, Strauch U, Burgess G, Spanton J, Martin SW et al.. (2011) The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.. Gut, 60 (8): (1068-75). [PMID:21317177] |
| 5. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S et al.. (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis.. N Engl J Med, 369 (8): (699-710). [PMID:23964932] |
| 6. Holzmann B, McIntyre BW, Weissman IL. (1989) Identification of a murine Peyer's patch--specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha.. Cell, 56 (1): (37-46). [PMID:2463092] |
| 7. Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, Lamb CA, Feagan BG, Panes J, Salas A et al.. (2014) Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.. Lancet, 384 (9940): (309-18). [PMID:24814090] |
| 8. Karecla PI, Bowden SJ, Green SJ, Kilshaw PJ. (1995) Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7).. Eur J Immunol, 25 (3): (852-6). [PMID:7705417] |
| 9. Cepek KL, Parker CM, Madara JL, Brenner MB. (1993) Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells.. J Immunol, 150 (8 Pt 1): (3459-70). [PMID:8468482] |